Healthcare and pharmaceutical group Duopharma Biotech Berhad has secured a three-year government contract worth approximately RM155.3 million to supply recombinant human insulin products and reusable insulin pens to facilities under the Ministry of Health (MOH).
The company announced that its wholly owned subsidiary, Duopharma (M) Sendirian Berhad (DMSB), had received and accepted a Letter of Award (LOA) from the Government for the supply of a package of insulin products to MOH healthcare facilities nationwide.
The contract covers the supply of short-acting, intermediate-acting and premixed recombinant human insulin 100 IU/ml penfill/refill products, together with reusable insulin pens.
Under the terms of the award, the contract will run for three years from June 3, 2026 until June 2, 2029, with an estimated total value of RM155.28 million.
Duopharma said a binding agreement came into effect upon DMSB’s acceptance of the LOA, while a formal contract is expected to be executed at a later date.
As part of the contract requirements, DMSB must provide an irrevocable performance bond of approximately RM2.59 million within 30 days of accepting the award.
The company noted that the government retains the right to terminate the contract under various circumstances, including failure to provide the performance bond, delays in product delivery, non-compliance with supply specifications, or breaches of tender conditions.
Duopharma said the contract aligns with its core business activities and strengthens its role in supporting the country’s diabetes treatment needs.
The group highlighted that Malaysia is estimated to have about 4.75 million people living with diabetes, with around 450,000 patients receiving recombinant human insulin treatment through government hospitals and clinics.
“The contract will enable DMSB to continue providing high-quality and cost-effective biosimilar insulin products to MOH facilities, contributing towards improved diabetes management in Malaysia,” the company said.
The pharmaceutical manufacturer added that the contract is expected to contribute positively to the group’s earnings throughout the contract period until its expiry in 2029.
In addition, DMSB will be required to participate in the government’s Professional Training and Education for Growing Entrepreneurs (PROTÉGÉ) programme at no cost to the government as part of the contract obligations.
